The IL-17/IL-23 axis of inflammation in cancer: Friend or foe?

Current Opinion in Investigational Drugs

Volumn 10, Issue 6, 2009, Pages 543-549

  Martin Orozco, Natalia ^a   Dong, Chen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer immunity; IL 17; IL 23; Immunotherapy; Th17

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HUMAN; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; NATURAL KILLER CELL; NONHUMAN; REVIEW; TH17 CELL; TUMOR IMMUNITY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-23; NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 67650684023     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Coussens LM, Werb Z: Infammation and cancer. Nature (2002) 420(6917):860-867.
2. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related infammation. Nature (2008) 454(7203):436-444.
3. Engels EA: Infammation in the development of lung cancer: Epidemiological evidence. Expert Rev Anticancer Ther (2008) 8(4):605-615.
4. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO: Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer (2000) 85(4):498-502.
5. Kuper HE, Tzonou A, Kaklamani E, Hadziyannis S, Tasopoulos N, Lagiou P, Trichopoulos D, Stuver S: Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays. Cancer Causes Control (2000) 11(2):171-175.
6. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A: Pathways connecting infammation and cancer. Curr Opin Genet Dev (2008) 18(1):3-10.
7. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD: Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 450(7171):903-907.
8. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21(2):137-148.
9. Hunter CA: New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol (2005) 5(7):521-531.
10. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S et al: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune infammation of the brain. Nature (2003) 421(6924):744-748.
11. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ: Divergent pro- and anti-infammatory roles for IL-23 and IL-12 in joint autoimmune infammation. J Exp Med (2003) 198(12):1951-1957.
12. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffths A, Dassopoulos T et al: A genome-wide association study identifes IL 23R as an infammatory bowel disease gene. Science (2006) 314(5804):1461-1463.
13. Latiano A, Palmieri O, Valvano MR, D'Inca R, Cucchiara S, Riegler G, Staiano AM, Ardizzone S, Accomando S, de Angelis GL, Corritore G et al: Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset infammatory bowel disease in Italy. World J Gastroenterol (2008) 14(29):4643-4651.
14. Wang K, Zhang H, Kugathasan S, Annese V, Bradfeld JP, Russell RK, Sleiman PM, Imielinski M, Glessner J, Hou C, Wilson DC et al: Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet (2009) 84(3):399-405.
15. Nair RP, Duffn KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A et al: Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet (2009) 41(2):199-204.
16. Ouyang W, Kolls JK, Zheng Y: The biological functions of T helper 17 cell effector cytokines in infammation. Immunity (2008) 28(4):454-467.
17. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T-helper type 1 and 2 lineages. Nat Immunol (2005) 6(11):1123-1132.
18. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C et al: A distinct lineage of CD4 T cells regulates tissue infammation by producing interleukin 17. Nat Immunol (2005) 6(11):1133-1141.
19. Dong C: TH17 cells in development: An updated view of their molecular identity and genetic programming. Nat Rev Immunol (2008) 8(5):337-348.
20. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune infammation. J Exp Med (2005) 201(2):233-240.
21. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ, Cua DJ: The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 10(3):314-324.
22. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 441(7090):235-238.
23. H17 lineage. Nature (2006) 441(7090):231-234.
24. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFβ in the context of an infammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 24(2):179-189.
25. H17 cells. Nature (2007) 448(7152):484-487.
26. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C et al: Essential autocrine regulation by IL-21 in the generation of infammatory T cells. Nature (2007) 448(7152):480-483.
27. H17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol (2007) 8(9):967-974.
28. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C: Critical regulation of early Th17 cells differentiation by interleukin-1 signaling. Immunity (2009) 30(4):576-587.
29. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C: Th17 cells promote pancreatic infammation but only induce diabetes effciently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol (2009) 39(1):216-224.
30. Nurieva R, Yang XO, Chung Y, Dong C: Cutting edge: In vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J Immunol (2009) 182(5):2565-2568.
31. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT: Late developmental plasticity in the T-helper 17 lineage. Immunity (2009) 30(1):92-107.
32. Bending D, De La Pena H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B, Cooke A: Highly purifed Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest (2009): doi:10.1172/JCI37865.
33. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K: Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity (2005) 22(3):285-294.
34. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, Berzins SP, Smyth MJ, Godfrey DI: Diverse cytokine production by NKT cell subsets and identifcation of an IL-17-producing CD4-NK1.1-NKT cell population. Proc Natl Acad Sci USA (2008) 105(32):11287-11292.
35. Shalom-Barak T, Quach J, Lotz M: Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem (1998) 273(42):27467-27473.
36. Schwandner R, Yamaguchi K, Cao Z: Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med (2000) 191(7):1233-1240.
37. Chang SH, Park H, Dong C: Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem (2006) 281(47):35603-35607.
38. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, Gaffen SL: Functional cooperation between interleukin-17 and tumor necrosis factor-α is mediated by CCAAT/Enhancer-binding protein family members. J Biol Chem (2004) 279(4):2559-2567.
39. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH, Schluns KS, Broaddus RR, Zhu Z, Dong C et al: Regulation of infammatory responses by IL-17F. J Exp Med (2008) 205(5):1063-1075.
40. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS, Watowich SS, Feng XH et al: Molecular antagonism and plasticity of regulatory and infammatory T cell programs. Immunity (2008) 29(1):44-56.
41. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, Nojima Y: Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinfammatory cytokine. Arthritis Rheum (2005) 52(4):1037- 1046.
42. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N et al: Interleukin-22, a member of the IL-10 subfamily, induces infammatory responses in colonic subepithelial myofbroblasts. Gastroenterology (2005) 129(3):969-984.
43. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R: IL-22 increases the innate immunity of tissues. Immunity (2004) 21(2):241-254.
44. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, Kasman I, Winer J, Modrusan Z, Danilenko DM, Ouyang W et al: The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol (2007) 178(4):2229-2240.
45. Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M, Aono T: Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun (2001) 282(3):735-738.
46. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ: Expression and function of pro-infammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate (2003) 56(3):171-182.
47. Ciree A, Michel L, Camilleri-Broet S, Jean Louis F, Oster M, Flageul B, Senet P, Fossiez F, Fridman WH, Bachelez H, Tartour E et al: Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer (2004) 112(1):113-120.
48. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, Seikour A, Charachon A, Karoui M, Leroy K, Farcet JP et al: High prevalence of Foxp3 and IL-17 in MMR-profcient colorectal carcinomas. Gut (2008) 57(6): 772-779.
49. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M: IL-23 promotes tumour incidence and growth. Nature (2006) 442(7101):461-465.
50. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG: Phenotypic analysis of prostate-infltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 14(11):3254-3261.
51. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W: Cutting edge: Th17 and regulatory T-cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 178(11):6730-6733.
52. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF: Generation and regulation of human CD4+ IL-17-producing T-cells in ovarian cancer. Proc Natl Acad Sci USA (2008) 105(40):15505-15510.
53. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G: The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun (2008) 374(3):533-537.
54. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA et al: Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 68(10):3915- 3923.
55. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT: Interleukin-17 promotes angiogenesis and tumor growth. Blood (2003) 101(7): 2620-2627.
56. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H et al: IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 175(9):6177-6189.
57. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, Banchereau J et al: Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 59(15):3698-3704.
58. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H: Regulation of the IL-23 and IL-12 balance by STAT3 signaling in the tumor microenvironment. Cancer Cell (2009) 15(2):114-123.
59. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E: Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 99(6):2114-2121.
60. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C: Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res (2006) 66(12):6395-6404.
61. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL, Yu JS: Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res (2006) 66(17):8887-8896.
62. Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B et al: Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 176(9):5213-5222.
63. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L et al: Tumor-specifc Th17-polarized cells eradicate large established melanoma. Blood (2008) 112(2):362-373.
64. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, Dong C et al: Generation of T follicular helper cells is mediated by interleukin-21 but independent of T-helper 1, 2, or 17 cell lineages. Immunity (2008) 29(1):138-149.
65. Andorsky DJ, Timmerman JM: Interleukin-21: Biology and application to cancer therapy. Expert Opin Biol Ther (2008) 8(9):1295-1307.
66. Thomas DA, Massague J: TGF-β directly targets cytotoxic T-cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 8(5):369-380.
67. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S: Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med (2005) 202(7):885-891.
68. Valzasina B, Piconese S, Guiducci C, Colombo MP: Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25-lymphocytes is thymus and proliferation independent. Cancer Res (2006) 66(8):4488- 4495.
69. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I: Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 112(6):2340-2352.
70. Lin WW, Karin M: A cytokine-mediated link between innate immunity, infammation, and cancer. J Clin Invest (2007) 117(5):1175- 1183.
71. Massague J: TGFβ in cancer. Cell (2008) 134(2):215-230.
72. Hong DS, Angelo LS, Kurzrock R: Interleukin-6 and its receptor in cancer: Implications for translational therapeutics. Cancer (2007) 110(9):1911-1928.